A timeline of the FDA approval of various disease modifying therapies for multiple sclerosis.
- 1993 Interferon β-1b SQ (Betaseron®)
- 1996 Interferon β-1a IM (Avonex® )
- 1996 Glatiramer acetate SQ (GA – Copaxone®)
- 2000 Mitoxantrone IV (Novantrone®)
- 2002 Interferon β-1a SQ (Rebif®)
- 2004 Natalizumab IV (Tysabri®); OFF market Feb. 2005, back on market July 2006
- 2010 Fingolimod PO (Gilenya®); Approved in 2018 for pediatric use.
- 2012 Teriflunomide PO (Aubagio®)
- 2013 Dimethyl fumarate PO (Tecfidera®)
- 2015 Generic glatiramer acetate SQ (Glatopa, Sandoz)
- 2016 X Daclizumab (Zinbryta) Removed from Market 2018
- 2017 Ocrelizumab IV (Ocrevus®); Generic glatiramer acetate (Mylan product)
- 2019 Siponimod PO (Mayzent®); Cladribine PO (Mavenclad®); Diroximel Fumarate PO (Vumerity®); Generic fingolimod x 3
- 2020 Ozanimod PO (Zeposia®); Ofatumumab SQ (Kesimpta®); Monomethyl fumarate (Bafiertam®); Generic dimethyl fumarate (Mylan)
